The core and extended Adjuvant teams are anchored by experienced venture capital and private equity investors, global public health leaders, disease-specific technical experts, and pharmaceutical industry veterans. Our deep ties to the global health community and our long-standing relationships with major funders and decision-makers are essential components of our investment sourcing and execution process.
Founder and Managing Partner / New York
Prior to his role at Adjuvant and his efforts to finance global health R&D programs on behalf of the Bill & Melinda Gates Foundation, Glenn was an Executive Director in J.P. Morgan’s Social Finance unit, where he helped the firm’s non-profit clients maximize the financial resources available to advance their missions. He served in similar capacities at J.P. Morgan for more than a decade before leaving to focus exclusively on financing public health innovations.
At Adjuvant, Glenn oversees the firm’s investments in VitriVax (board member), Univercells (board member), Themis (acquired by Merck in 2020), X-Vax (board observer), InDevR (board member), and Codagenix (board member). He is also actively engaged with the Research Investment for Global Health Technology Fund (RIGHT Fund) as a board member and a champion of leveraging the strengths of South Korea’s life sciences industry to bring new public health innovations to market.
True to his conviction in the power of capital markets and impact investing to drive improvements in livelihoods around the world, he recently added a board seat at WaterEquity to his commitments.
Glenn earned an AB in public policy from the Princeton School of Public and International Affairs.
Managing Partner / San Francisco
Jenny has worked in finance for more than 18 years, beginning as an investment banker advising corporate clients in mergers and acquisitions, and debt and equity financings at Goldman Sachs’ Hong Kong, New York, and San Francisco offices. She has always been passionate about improving the health and lives of those living in low- and middle-income countries and spent time working and living in Kenya and China. In Kenya, Jenny spent almost a year as a volunteer consultant for Technoserve, a non-profit business consultancy for small-holder farmers and small to medium businesses.
At Adjuvant, in addition to managing the firm’s operations and growth, Jenny oversees the firm’s investments in 54gene (board member), ChromaCode (board member) and Evofem Biosciences (board observer). She is also a fierce advocate for women’s health and serves on the Investment Advisory Committee at RHIA Ventures (formerly the Reproductive Health Investors’ Alliance).
In 2012, the Bill & Melinda Gates Foundation (BMGF) was expanding its strategic investment efforts from a pilot program to a larger scale fund. As part of a small but growing team, Jenny pushed the envelope on how private foundations could achieve charitable objectives by using philanthropic capital and program-related investments to complete equity, debt, structured finance, and guarantee investments in companies and investment funds. Jenny led transactions across the foundation’s focus areas in global health, agriculture, nutrition, and education. She represented BMGF’s interests on numerous boards including Kymab (sold to Sanofi for $1.1bn), Acrobatiq, Ustar Technologies, and Owl Ventures (USA).
Jenny graduated magna cum laude from Harvard University with an AB in History of Science. She lives in San Francisco with her husband and two young children.
Advisory Partner / San Diego
In addition to her role at Adjuvant, Kim is also currently a Partner at Domain Associates where she has been involved in cutting-edge therapeutic start-ups and has been a major part of identifying companies with promising molecular and companion diagnostics to support personalized medicine.
Present board memberships include Aspen Neuroscience, Epic Sciences, Evofem Biosciences, Obalon Therapeutics, Omniome, Seraphina, Sera Prognostics, Singular Genomics, and Truvian Sciences. She also helped to create and was formerly a board member of Syndax Pharmaceuticals and Tragara Pharmaceuticals. Kim was involved with Ariosa Diagnostics until the company was sold to Roche in January 2015, Corthera until the company was sold to Novartis in February 2010 and BiPar Sciences until that company was sold to Sanofi in April 2009.
Kim is also a Kauffman Fellow alum. Prior to Domain, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. Kim serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and is a former advisor to the Bill & Melinda Gates Foundation.
Co-Founder and Principal / New York
Kabeer co-founded Adjuvant Capital following his time at the Global Health Investment Fund (GHIF), where he led and helped manage the fund’s investments in Themis (now part of Merck), Univercells, Atomo Diagnostics (ASX: AT1), and Access Bio (KOSDAQ: 950130), among others. Prior to GHIF, Kabeer spent time at Metalmark Capital investing across the healthcare sector, as well as Greenhill & Co., where he advised on biopharmaceutical M&A transactions.Kabeer currently serves on the Board of Directors of MinervaX, AN2 Therapeutics, and Univercells Vaccines, while also supporting Adjuvant’s engagement on the Boards of Yisheng Biopharma and previously, Themis. He graduated with honors from the Stern School of Business at New York University.
Co-Founder and Principal / New York
Charlie co-founded Adjuvant Capital alongside colleagues from the Bill & Melinda Gates Foundation and the Global Health Investment Fund. He is an observer or involved with Adjuvant’s investments in Excision Biotherapeutics, ChromaCode, Evofem Biosciences (EVFM), and Minervax and serves on the boards of Codagenix and VitriVax.
Charlie is a Kauffman Fellow (Class 25) and serves as a board observer for Seraphina Therapeutics through his mentorship under Kim Kamdar (Class 8) of Adjuvant and Domain Associates.
Previously, Charlie was an investor at the Global Health Investment Fund where he was involved in the fund’s investments in EuBiologics, MDGH, IanTech (acquired by Zeiss), and Alydia Health.
Before joining GHIF, Charlie was with Artemis Capital Partners, where he made growth equity investments with a focus on scientific tools and instrumentation.
Previously, he lived in Haiti and worked at the country’s largest microfinance bank, Sevis Finansye Fonkoze, where he led financial and operational analysis efforts.
Outside of Adjuvant, Charlie has served on the boards of Sevis Finansye Fonkoze and Fonkoze USA. He is an advisor to New Incentives, a GiveWell top charity focused on improving routine vaccination rates in Nigeria.
Charlie is a graduate of the Virginia Polytechnic Institute. He lives in Brooklyn with his wife and daughter.
Principal / New York
Michael joined the Adjuvant investment team from the Bill & Melinda Gates Foundation (BMGF) where he worked with its Global Health Division and Strategic Investment Fund to structure investments into biotech companies, leading academic centers, and other non-profit organizations that have the goal of stimulating technological innovation in global health. Michael has experience investing in the development of drugs, vaccines, diagnostics, and health data solutions across a range of high-burden and neglected disease areas.
Before joining BMGF, Michael spent several years covering the specialty pharmaceuticals sector as an equity research analyst at Piper Jaffray in New York. Michael started his career in the investment banking practice at Stifel where he focused on mergers and acquisitions advising. He earned a BA in International Relations from Johns Hopkins University.
Lilly deSouza Burr
Associate / New York
Lilly deSouza Burr
Lilly joined the Adjuvant investment team from Citi, where she was a senior associate in Citi’s healthcare investment banking group, advising clients across the biotech, pharma, medtech and services sectors on strategic and operational planning, M&A transactions and equity and debt financings. Prior to Citi, Lilly practiced law in the M&A group at Davis Polk & Wardwell, LLP. Lilly also spent time before law school at the Neurosciences Clinic at the Ottawa Hospital, where she managed a clinical neurosurgery practice and focused on spinal cord injury research.
She holds a JD from Georgetown University Law Center and a BS from the University of Ottawa.
Director of Finance and Compliance / New York
Evelyn is a senior financial professional and provides outsourced operational, regulatory, and audit and tax oversight services to Adjuvant. She has extensive experience in investment analysis and valuation, fundraising, SEC and other financial reporting, accounting, audit and tax.
Evelyn received a BS in Accounting from Binghamton University and an MBA from the Fordham Gabelli School of Business. She is a Certified Public Accountant in New York State.
Director of Operations / New York
David serves as the Head of Operations and Impact at Adjuvant Capital where he leads fund and impact operations including ESG integration and impact due diligence, measurement and management. He joined Adjuvant from Bridgespan, where he was a Manager on Bridgespan’s Impact Investing Management Team. As a member of this team, David helped lead Bridgespan’s efforts to partner with impact investors to develop their own impact due diligence systems, publish related insights, and speak about best practices. Outside of his impact investing projects, David worked with a diverse set of public health actors—including direct service organizations and funders such as The End Fund, Planned Parenthood, Last Mile Health, and the Robert Wood Johnson Foundation—to develop operating models, strategic plans, learning and innovation processes, and investment proposals.
Prior to joining Bridgespan, David worked as a Guyer Fellow at Save the Children (child health), a program analyst at the Ford Foundation (financial inclusion), and an investment analyst in McKinsey & Co.’s investment office (MIO Partners). David earned his MBA/MPH with honors (Tuck Scholar) from Dartmouth College where he was a Wilson Scholar and his BA cum laude with departmental distinctions from Yale University.
Gerard is an Operating Partner with Adjuvant Capital and has 25 years of experience in the vaccine industry, global health partnerships and consulting. As an Operating Partner with Adjuvant Capital, Gerard supports the Fund’s assessment of global health innovations, and support portfolio companies as they develop and deliver new products to improve public health outcomes in low- and middle-income countries.
Gerard has worked vaccine development and delivery for almost two decades, including leadership of the new vaccine planning function at Merck. He spent more than three years working at the Bill & Melinda Gates Foundation (BMGF) where he supported the HIV, TB, and malaria program teams, and worked closely with a range of partners including multinational corporations, emerging market manufacturers, the WHO, UNICEF, Gavi, and others to support delivery of new vaccines and polio eradication.
During his tenure at BMGF, Gerard negotiated several partnerships to drive access to new vaccines. He was responsible for assessments of new technologies for the inactivated polio vaccine (IPV) as well as partner/supplier assessments, providing leadership for technical, financial and legal diligence efforts for multiple manufacturers.
Gerard has served as a Senior Advisor to the Global Health Investment Fund since its inception in 2012, and provided diligence and operational support for four of the Fund’s investments.
Gerard has an MA (Engineering) and a M. Eng. (Manuf. Engineering) degree from Cambridge University, in addition to an MBA (Marketing & International Business) from the University of Michigan
Venture Partner / New York
Curt has been investing in healthcare companies for over 16 years. He has served as a board member or observer for many successful companies, including KAI Pharmaceuticals (sold to Amgen), Sirion Therapeutics (sold to B&L and Alcon), Impulse Monitoring (sold to NuVasive), TransMolecular (sold to Morphotek), Estech (sold to Atricure), Coherex (sold to J&J), Exagen Diagnostics, SafeOp and others. Curt was previously a managing director at Tullis Health Investors and a vice president at Investor Growth Capital. He holds a BS in economics from Brigham Young University, and both MD and MBA degrees from Columbia University.
Mark Sullivan has 11 years executive management, advisory board, and board of directors experience in biotechnology and 28 years of experience in clinical development within the biotechnology, large pharmaceutical, contract services, and academic sectors. His drug development experience encompasses project leadership of five biopharmaceutical products, with his most recent program securing FDA approval in June 2018, and extensive practical experience implementing clinical studies across all stages of development.
Mr. Sullivan led the team responsible for one of GHIF’s more rewarding social and financial investments: seeing the moxidectin program through the final stages of development and securing regulatory approval for the drug as the first new treatment for onchocerciasis registered with the FDA in more than 20 years.
Senior Advisor / San Francisco
Dr. Sophie Allauzen has 20 years of international experience in R&D, business development, and portfolio management in various diagnostic industries managing the full life-cycle of novel diagnostic products (R&D, planning, commercialization, and registration) in developed and developing worlds. Sophie’s experience includes the Bill & Melinda Gates Foundation where she oversaw malaria and a portfolio of neglected diseases diagnostic programs, Novartis Diagnostics as Head of Blood Testing running the NAT/Immunohematology product portfolio, and Bio-Rad managing the R&D department for the development of bead multi-array immuno-assays. Prior moving to the U.S., Sophie spent five years at Sanofi Diagnostics Pasteur in France, in R&D working on the development of various tests for infectious diseases.
Sophie holds a PhD in biochemistry/immunology from Montpellier University, France, directed toward auto-immune disease mechanisms, and completed her postdoc fellow position in allergy at University of Minnesota.
She is currently an independent consultant based in San Francisco, CA.
Senior Advisor / Boston
Christian W. Mandl, Ph.D., M.D. is a Senior Advisor to Adjuvant Capital, and he provides consulting services to industry partners and non-profit organizations around the world for vaccine and viral vector programs. Previously he was the Senior Vice President of Research for VIR Biotechnology (San Francisco, CA). Until 2015, he was Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines, where he led a global team of more than 300 discovery and clinical researchers developing a broad range of viral and bacterial vaccines, adjuvants and delivery platforms including the self-amplifying RNA technology (SAM®), which he initiated inspired by his previous academic research.
Prior to joining Novartis in 2008, Christian was Professor and Assistant Head of the Clinical Institute of Virology at Medical University of Vienna. His academic research focused on molecular mechanisms of RNA viruses, their interactions with host organisms targeting novel medical applications, enabling new antiviral strategies and applications in vaccine development or viral gene vectors. He is a world-renowned expert in the molecular biology of flaviviruses and RNA vaccines. He has authored more than 100 scientific publications, and is an inventor on patents related to a marketed tick-borne encephalitis (flavivirus) vaccine, the SAM technology, and other antiviral approaches. Christian holds a PhD and MD from University of Vienna, and a Master of Science (Biochemistry) from Pennsylvania State University. He earned his postdoctoral lecturer qualification (Habilitation) in Molecular Virology and was certified as a Medical Specialist in Virology by the Austrian Medical Association.
His engagement with the health care industry and public health organizations includes roles as a Co-founder and Chair, Scientific Advisory Board for Tiba Biotech (Cambridge, MA), Chair, Scientific Advisory Board for Themis Biotech (Vienna, Austria), and Chair, Scientific Advisory Group for the International Vaccine Institute (Seoul, Korea).
Jim Robinson is an accomplished biologics manufacturing expert with decades of industry experience across a wide range of institutions. From 2010 to 2015, he served as Vice President, Global Technical Operations, Vaccines, Biological and Sterile Products for Merck & Co., Inc., where he oversaw improvements to the company’s manufacturing operations in order to increase supply performance and capacity realization for the vaccine, biologics and sterile products franchises (combined $11 billion in annual sales). From 2007 to 2010, he was Vice President, Technical and Quality Operations at Novavax, Inc., managing a 40-person biotechnology team focused on recombinant virus-like particle vaccines. The prior 20 years were spent in various positions with Sanofi Pasteur, including, from 1998 to 2006, as Vice President, Industrial Operations. Mr. Robinson has been granted various international patents, serves on a number of Scientific Advisory Boards and Councils, such as his Vice Chair role on CEPI’s Scientific Advisory Committee, and is the author of an array of publications covering vaccines and biologics manufacturing. He holds Master’s and Bachelor’s degrees in Chemical Engineering from Lehigh University.
Senior Advisor / DC
Peter A. Patriarca, M.D., is the Principal of Immuno-Vax, LLC, and a senior affiliate consultant with Biologics Consulting Group, Inc. (Alexandria, Virginia). He has provided technical and regulatory consulting services for all phases of vaccine and other biological products development for the past 14 years for over 500 projects. Prior to consulting, Dr. Patriarca was Corporate Head and Vice President, Worldwide Regulatory Affairs and Pharmacovigilance at MedImmune, Inc. (2001-2005) and also served as Medical Officer in the U.S. Public Health Service at the Centers for Disease Control and Prevention (1980-1992) and the US Food and Drug Administration (1993-2001). At FDA, Dr. Patriarca served, among other positions, as Director of the Division of Viral Products in the Office of Vaccines Research and Review (OVRR), CBER. In that capacity, he oversaw research and review activities of more than 100 scientific staff in eight laboratories, and was intimately involved with regulatory decisions and policy affecting vaccine development and licensure. While at CDC, Dr. Patriarca was assigned to the National Immunization Program, where, among other positions, he served as the Chief Medical Epidemiologist in the Influenza Division and the first head of CDC’s program in support of the Global Poliomyelitis Eradication Initiative. He has authored more than 100 peer-review publications and has served on multiple scientific advisory bodies for CDC, WHO, the Bill and Melinda Gates Foundation, the American Academy of Pediatrics, the National Academy of Sciences, and numerous pharmaceutical companies.
Senior Advisor / San Diego
Dr. Marrinucci is a life science entrepreneur with a passion for introducing diagnostic technologies with potential to transform human health. She is a Senior advisor to Adjuvant Capital, drawing upon a wealth of experience in the diagnostics industry and a history of entrepreneurial success.
She joined the founding team at Truvian Sciences in late 2015. As Chief Operating Officer, she oversees manufacturing, operations, program management, and scientific affairs. Prior to Truvian, Dr. Marrinucci developed a novel circulating tumor cell technology at Epic Sciences, which she founded in 2008. During her tenure as Epic’s chief scientific officer, she oversaw diagnostic collaborations with pharma and established and led Epic’s clinical laboratory and assay development operations. In addition to her role at Truvian, Dr. Marrinucci serves as board member for Connect as well as an advisor for Lynx Biosciences. She has been named to MIT Technology Review’s Top 35 Innovators Under 35, Foreign Policy’s Top 100 Leading Global Thinkers, and PharmaVoice 100. She also was named a 2016 Life Science Catalyst Award winner, gaining recognition from Biocom and San Diego Venture Group as one of 10 individuals sparking meaningful change to human health. She has authored dozens of peer reviewed publications and is an inventor on 12 patents. Dr. Marrinucci hold a B.S. in chemistry from University of Vermont and a Ph.D. from The Scripps Research Institute in chemical biology.
Senior Advisor / San Diego
Michael R. Hodges, M.D., BSc.is an infectious disease clinician and RNA medicines drug development executive with 30 years of experience within the biopharmaceutical industry. He is currently Chief Medical Officer (CMO) at Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. In addition, he is a member of the science advisory boards of Arcturus therapeutics, Exicure therapeutics and eFFECTOR therapeutics. Prior to Amplyx he was the CMO for two RNA platform companies, Santaris A/S and Altair Therapeutics Inc., developing drugs for infectious diseases, cancer, metabolic and respiratory diseases. Previously, he served in Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. He was a Non-Executive Director of F2G, an infectious disease biotechnology company from 2010-2014. Dr. Hodges earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.